Peanut OIT: Getting Your Practice Ready

Price: FREE for members and $25 for non-members

This is the archived recorded version of the live ACAAI webinar.

With new approaches being developed for management of peanut allergy, it is imperative that allergists learn how to maximize their practice set up in offering this new treatment. This webinar will discuss how to maximize your practice set up to offer this new treatment. Experts Michael Manning, MD, FACAAI and Alan Goldsobel, MD, FACAAI will cover setting up SOPs and protocols, office logistics and safety considerations.

This webinar was supported by Aimmune.

Learning Objectives

After completing this webinar, participants should be able to:

  1. Be familiar with causes of infantile anaphylaxis
  2. Recognize infant anaphylaxis and know the difference compared to children and adults
  3. Provide correct treatment and prevention procedures for infants with a history of anaphylaxis
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Michael Manning, MD
Aimmune: Consultant, Clinical Research; Honorarium, Contract research grant
DBV Technologies: Consultant; Honorarium
Takeda/Shire/Dyax: Consultant, Advisory Board, Clinical Research, Speaker; Honorarium, Consulting fees, Contract research grant
Pharming: Consultant, Advisory Board, Speaker; Honorarium, Consulting fees

Alan Goldsobel, MD, FACAAI
Aimmune: Contracted Research, Advisory Board member; Contracted research payment, Honoraria

Course summary
Course opens: 
08/21/2019
Course expires: 
08/20/2022
Cost:
$25.00
Rating: 
0

Price

Cost:
$25.00
Please login or create an account to take this course.